Ubs Group Ag Chemomab Therapeutics Ltd. Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Chemomab Therapeutics Ltd. stock. As of the latest transaction made, Ubs Group Ag holds 883 shares of CMMB stock, worth $1,183. This represents 0.0% of its overall portfolio holdings.

Number of Shares

883

Previous 485 82.06%

Holding current value

$1,183

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	BUY	$1.09 - $2.44 $433 - $971	398 Added 82.06%	883 $0
Q4 2024 Feb 14, 2025	SELL	$1.13 - $2.02 $2,037 - $3,642	-1,803 Reduced 78.8%	485 $0
Q3 2024 Nov 14, 2024	BUY	$0.93 - $2.46 $2,127 - $5,628	2,288 New	2,288 $3,000
Q3 2023 Nov 09, 2023	BUY	$0.9 - $1.42 $116 - $183	129 Added 1075.0%	141 $0
Q2 2023 Aug 11, 2023	SELL	$1.0 - $1.84 $399 - $734	-399 Reduced 97.08%	12 $0
Q1 2023 May 12, 2023	SELL	$1.44 - $2.94 $6,073 - $12,400	-4,218 Reduced 91.12%	411 $0
Q4 2022 Feb 08, 2023	SELL	$1.9 - $3.2 $492 - $828	-259 Reduced 5.3%	4,629 $14,000
Q3 2022 Nov 10, 2022	BUY	$2.33 - $4.0 $11,389 - $19,552	4,888 New	4,888 $12,000
Q2 2022 Aug 10, 2022	SELL	$2.58 - $4.88 $2,283 - $4,318	-885 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$3.53 - $7.2 $3,388 - $6,912	-960 Reduced 52.03%	885 $4,000
Q4 2021 Feb 14, 2022	BUY	$6.41 - $11.13 $602 - $1,046	94 Added 5.37%	1,845 $13,000
Q3 2021 Nov 15, 2021	BUY	$11.08 - $19.17 $17,860 - $30,902	1,612 Added 1159.71%	1,751 $19,000
Q2 2021 Aug 13, 2021	SELL	$16.07 - $55.0 $11,168 - $38,225	-695 Reduced 83.33%	139 $3,000
Q1 2021 May 12, 2021	BUY	$27.2 - $127.36 $22,684 - $106,218	834 New	834 $24,000

Others Institutions Holding CMMB

# of Institutions

Shares Held

3.72M

Call Options Held

Put Options Held

View Full List

About Chemomab Therapeutics Ltd.

Ticker CMMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,431,700
Market Cap $15.3M
Description
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (...

More about CMMB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account